Amberstone Biosciences Inc.
Irvine, CA
- UEI
- RYHMZ2NLW2C1
- CAGE
- 7RYP6
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 15300 Barranca Pkwy #100, Irvine, CA 92618, USA
- Website
- amberstonebio.com
- Founded
- 2018
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Promab Biotechnologies, Inc. | Richmond, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Abalone Bio, Inc. | — | — |
| Panorama Research Incorporated | Sunnyvale, CA | — |
| Novab, Inc. | Tucker, GA | 621511 Medical Laboratories |
| Avantgen Inc. | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Amberstone Biosciences is a biotechnology company based in Irvine, CA that is focused on transforming the immunotherapy landscape by introducing a safer class of therapeutic agents. Their technology, T MATE™, allows them to target tumors without damaging healthy cells. Amberstone Biosciences is a minority-owned, Asian-Pacific American owned, for-profit organization registered to receive federal awards.
Through its federal grant awards, Amberstone Biosciences has primarily provided research and development services related to bispecific antibody therapeutics and functional screening platforms. The company has received awards from agencies like the National Science Foundation (NSF) and the National Institutes of Health (NIH) under programs such as the Small Business Innovation Research (SBIR) program. Notable projects include developing a single-cell interaction platform to accelerate the discovery of bispecific antibodies, identifying broad-spectrum bispecific antibodies against SARS-CoV-2, SARS-CoV, and MERS-CoV using high-throughput functional screening, and optimizing bispecific antibody leads for potential clinical development as COVID-19 therapeutics or passive vaccines. Amberstone Biosciences has received over $2.6 million in federal grant funding to support these research initiatives aimed at advancing novel biopharmaceutical products and technologies.
Quick answers
Is Amberstone Biosciences Inc. registered in SAM.gov?
Yes. Amberstone Biosciences Inc.'s SAM.gov registration is active through September 6, 2027.
What is Amberstone Biosciences Inc.'s most recent federal award?
Amberstone Biosciences Inc.'s most recent federal grant award is Sbir phase II: a single-cell-interaction platform for accelerating discovery of bispecific antibodies (2051931), from National Science Foundation, on April 15, 2021.
On GovTribe
See Amberstone Biosciences Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors